Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;10(1):35-56.
doi: 10.1007/s13300-018-0550-x. Epub 2018 Dec 18.

Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review

Shazli Azmi  1 , Kariem T ElHadd  2 , Andrew Nelson  3 , Adam Chapman  3 , Frank L Bowling  1 , Anughara Perumbalath  3 , Jonathan Lim  3 , Andrew Marshall  1 , Rayaz A Malik  1   4 , Uazman Alam  5   6   7
Affiliations
Review

Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review

Shazli Azmi et al. Diabetes Ther. 2019 Feb.

Abstract

Pregabalin is a first-line treatment in all major international guidelines on the management of painful diabetic neuropathy (pDPN). Treatment with pregabalin leads to a clinically meaningful improvement in pain scores, offers consistent relief of pain and has an acceptable tolerance level. Despite its efficacy in relieving neuropathic pain, more robust methods and comprehensive studies are required to evaluate its effects in relation to co-morbid anxiety and sleep interference in pDPN. The sustained benefits of modulating pain have prompted further exploration of other potential target sites and the development of alternative GABAergic agents such as mirogabalin. This review evaluates the role of pregabalin in the management of pDPN as well as its potential adverse effects, such as somnolence and dizziness, which can lead to withdrawal in ~ 30% of long-term use. Recent concern about misuse and an increase in deaths linked to its use has led to demands for reclassification of pregabalin as a class C controlled substance in the UK. We believe these demands need to be tempered in relation to the difficulties it would create for repeat prescriptions for the many millions of patients with pDPN for whom pregabalin provides benefit.Plain Language Summary: Plain language summary available for this article.

Keywords: Anxiety; GABAergic therapy; Neuropathic pain; Painful diabetic neuropathy; Pregabalin; Sleep interference.

PubMed Disclaimer

References

    1. Andruszkiewicz R, Silverman RB. 4-Amino-3-alkylbutanoic acids as substrates for gamma-aminobutyric acid aminotransferase. J Biol Chem. 1990;265(36):22288–22291. - PubMed
    1. Pritchard N, Edwards K, Russell AW, Perkins BA, Malik RA, Efron N. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. Diabetes care. 2015:dc142114. - PubMed
    1. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014;5(1):38–56. - PMC - PubMed
    1. D’Arcy Y, McCarberg B, Parsons B, Behar R, Thorpe A, Alexander A. Pregabalin for the treatment of neuropathic pain: a narrative review for primary care providers. Curr Med Res Opin. 2017;33(8):1353–1359. - PubMed
    1. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28(9):835–854. - PubMed

LinkOut - more resources